title: The reproductive and metabolic effect of rosiglitazone on Chinese women with polycystic ovarian syndrome--a double-blind randomized placebo-controlled study.
abstract: OBJECTIVE
  To investigate whether an insulin sensitizer has any effect on amenorrhea and clinical and biochemical hyperandrogenism in Chinese women with polycystic ovarian syndrome (PCOS).
  
  
  METHODS
  Randomized controlled double-blind trial.
  
  
  METHODS
  A tertiary referral center, Hong Kong.
  
  
  METHODS
  Chinese women who fulfilled the Rotterdam criteria of PCOS (n = 70).
  
  
  METHODS
  Rosiglitazone 4 mg daily for the first month followed by 4 mg twice daily for 11 months.
  
  
  METHODS
  Menstrual status as well as clinical and biochemical hyperandrogenism.
  
  
  RESULTS
  There is a significantly higher rate of regular menses among the treatment arm (16 [50.0%] of 32 vs 4 [11.8%] of 34) at 6 months and the improvement appeared to be sustained (10 [41.7%] of 24 vs 6 [20.0%] of 30) at 12 months. There was no change in the acne and hirsutism scores as well as serum T levels in both arms.
  
  
  CONCLUSIONS
  We found a possible benefit in menstrual cyclicity but a lack of improvement in hyperandrogenism in our Chinese population.
  
  
  BACKGROUND
  ChiCTR-TRC-09000670 (Chinese Clinical Trial Registry).
authors: Department of Obstetrics and Gynecology, Prince of Wales Hospital, Hong Kong, People's Republic of China.
authors: Po Mui
authors: PM
authors: Lam
authors: Wing Hung
authors: WH
authors: Tam
authors: Ronald Ching Wan
authors: RC
authors: Ma
authors: Lai Ping
authors: LP
authors: Cheung
authors: Michelle Hang Yuet
authors: MH
authors: Tsui
authors: Peter Chun Yip
authors: PC
authors: Tong
authors: Francis Chun Chung
authors: FC
authors: Chow
authors: Christopher Wai Kei
authors: CW
authors: Lam
authors: Michael Ho Ming
authors: MH
authors: Chan
authors: Juliana Chung Ngor
authors: JC
authors: Chan
authors: Christopher John
authors: CJ
authors: Haines
mesh_terms: D000328:Adult; D000568:Amenorrhea / Q000097:blood / Q000188:drug therapy* / Q000208:ethnology / Q000503:physiopathology; D044466:Asian People; D016009:Chi-Square Distribution; D004311:Double-Blind Method; D005260:Female; D006723:Hong Kong / Q000453:epidemiology; D006801:Humans; D017588:Hyperandrogenism / Q000097:blood / Q000188:drug therapy* / Q000208:ethnology / Q000503:physiopathology; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008597:Menstrual Cycle / Q000187:drug effects; D015990:Placebo Effect; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000188:drug therapy* / Q000208:ethnology / Q000503:physiopathology; D000077154:Rosiglitazone; D013739:Testosterone / Q000097:blood; D045162:Thiazolidinediones / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D013739:Testosterone